[Pharmacogenetics].
D000743:Anemia, Hemolytic / Q000139:chemically induced; D000983:Antipyrine / Q000009:adverse effects; D004247:DNA / Q000378:metabolism; D064420:Drug-Related Side Effects and Adverse Reactions; D005060:Europe; D005955:Glucosephosphate Dehydrogenase Deficiency; D005978:Glutathione / Q000378:metabolism; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects; D010597:Pharmacogenetics; D010615:Phenacetin / Q000009:adverse effects; D011115:Polyneuropathies / Q000139:chemically induced; D011319:Primaquine / Q000009:adverse effects; D011803:Quinine / Q000009:adverse effects; D044469:Racial Groups; D013449:Sulfonamides / Q000009:adverse effects
D013449:Sulfonamides; D004247:DNA; D011803:Quinine; D010615:Phenacetin; D005978:Glutathione; D011319:Primaquine; D000983:Antipyrine; D007538:Isoniazid
Pharmakogenetik.